JP2025078629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025078629A5 JP2025078629A5 JP2025012821A JP2025012821A JP2025078629A5 JP 2025078629 A5 JP2025078629 A5 JP 2025078629A5 JP 2025012821 A JP2025012821 A JP 2025012821A JP 2025012821 A JP2025012821 A JP 2025012821A JP 2025078629 A5 JP2025078629 A5 JP 2025078629A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- antibody
- domain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19206959.9 | 2019-11-04 | ||
| EP19206959.9A EP3816185A1 (en) | 2019-11-04 | 2019-11-04 | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| JP2022524675A JP2023501146A (ja) | 2019-11-04 | 2020-11-04 | 多重特異性抗体 |
| PCT/EP2020/080941 WO2021089609A1 (en) | 2019-11-04 | 2020-11-04 | Multispecific antibody |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524675A Division JP2023501146A (ja) | 2019-11-04 | 2020-11-04 | 多重特異性抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025078629A JP2025078629A (ja) | 2025-05-20 |
| JP2025078629A5 true JP2025078629A5 (https=) | 2025-10-27 |
Family
ID=68426333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524675A Pending JP2023501146A (ja) | 2019-11-04 | 2020-11-04 | 多重特異性抗体 |
| JP2025012821A Pending JP2025078629A (ja) | 2019-11-04 | 2025-01-29 | 多重特異性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524675A Pending JP2023501146A (ja) | 2019-11-04 | 2020-11-04 | 多重特異性抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220411536A1 (https=) |
| EP (2) | EP3816185A1 (https=) |
| JP (2) | JP2023501146A (https=) |
| KR (1) | KR20220092949A (https=) |
| CN (1) | CN114981306A (https=) |
| AU (1) | AU2020379182A1 (https=) |
| CA (1) | CA3159904A1 (https=) |
| IL (1) | IL292727A (https=) |
| WO (1) | WO2021089609A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3634998B8 (en) * | 2017-06-05 | 2025-04-09 | Numab Therapeutics AG | Anti-cd3 epsilon antibodies |
| WO2022136693A1 (en) | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| EP4341294A1 (en) * | 2021-05-21 | 2024-03-27 | BeiGene Switzerland GmbH | Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use |
| IL310217A (en) * | 2021-07-23 | 2024-03-01 | Akeso Biopharma Inc | Pharmaceutical composition and use |
| CN117730103A (zh) * | 2021-08-02 | 2024-03-19 | 盛禾(中国)生物制药有限公司 | 一种多特异性抗原结合蛋白及其应用 |
| TWI876227B (zh) * | 2021-11-17 | 2025-03-11 | 大陸商南京再明醫藥有限公司 | 多特異性抗體及其藥物用途 |
| KR20240133746A (ko) * | 2022-01-09 | 2024-09-04 | 아이-맵 바이오파마 컴파니 리미티드 | 다중특이적 작제물 및 이의 용도 |
| IL314169A (en) * | 2022-01-26 | 2024-09-01 | Zymeworks Bc Inc | Trispecific immunomodulatory T cell engager proteins |
| CN118574857A (zh) * | 2022-01-27 | 2024-08-30 | 岩唐生物科技(杭州)有限责任公司 | 靶向cd3的多特异性抗体及其应用 |
| WO2024036207A2 (en) * | 2022-08-11 | 2024-02-15 | University Of Florida Research Foundation, Incorporated | Rabbit monoclonal antibodies targeting multiple myeloma cell surface antigens |
| WO2024061297A1 (en) * | 2022-09-22 | 2024-03-28 | Shanghai Henlius Biotech , Inc. | Anti-b7h3 antibodies, multispecific antibodies and methods of use |
| WO2024197709A1 (zh) * | 2023-03-30 | 2024-10-03 | 中国科学院深圳先进技术研究院 | 一种t细胞衔接器及其制备方法和应用 |
| CN121398845A (zh) * | 2023-07-14 | 2026-01-23 | 嘉和生物药业有限公司 | 抗pd-1/ctla-4/tigit三特异性抗体及其用途 |
| AU2024317606A1 (en) * | 2023-07-29 | 2026-02-26 | Chimagen Biosciences, Ltd | Modified type e multi-specific antibodies |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| EP1240337B1 (en) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| AU2002335930B2 (en) | 2001-03-09 | 2005-07-28 | Morphosys Ag | Serum albumin binding moieties |
| EP1576172A2 (en) | 2002-06-21 | 2005-09-21 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| TW200607523A (en) | 2004-06-01 | 2006-03-01 | Domantis Ltd | Drug compositions, fusions and conjugates |
| KR20060095385A (ko) | 2005-02-28 | 2006-08-31 | 엘지전자 주식회사 | 세탁기의 헹굼 행정 제어 방법 |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| WO2011006915A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| WO2016011069A1 (en) * | 2014-07-15 | 2016-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of cd38 agonists (antibodies) |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| IL293435B1 (en) | 2015-06-15 | 2026-04-01 | Numab Therapeutics AG | Heterodimeric multispecific antibody format |
| KR20180096789A (ko) | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| CN109310766A (zh) * | 2016-02-26 | 2019-02-05 | 伊蒙纽斯私人有限公司 | 多特异性分子 |
| EP3445788B1 (en) | 2016-04-22 | 2022-01-19 | Alligator Bioscience AB | Novel bispecific polypeptides against cd137 |
| RU2769282C2 (ru) * | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| AR110348A1 (es) * | 2016-12-07 | 2019-03-20 | Agenus Inc | Anticuerpos y métodos de su utilización |
| WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| SG11201911527QA (en) * | 2017-06-05 | 2020-01-30 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| US12202911B2 (en) * | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| CN120248120A (zh) * | 2017-10-10 | 2025-07-04 | 努玛治疗有限公司 | 靶向pdl1的抗体及其使用方法 |
| EP3470429A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting pdl1 and methods of use thereof |
| EP3470426A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| CA3089230A1 (en) * | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| CN109942704B (zh) * | 2019-04-12 | 2023-01-20 | 深圳普瑞金生物药业股份有限公司 | Hsa单域抗体、核酸及试剂盒 |
| KR20230018397A (ko) * | 2020-05-29 | 2023-02-07 | 누맙 세러퓨틱스 아게 | 다중 특이적 항체 |
| EP3988568A1 (en) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| IL303171A (en) * | 2020-12-23 | 2023-07-01 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| JP2024504471A (ja) * | 2021-02-02 | 2024-01-31 | ヌマブ セラピューティックス アーゲー | Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体 |
-
2019
- 2019-11-04 EP EP19206959.9A patent/EP3816185A1/en not_active Ceased
-
2020
- 2020-11-04 US US17/771,836 patent/US20220411536A1/en active Pending
- 2020-11-04 JP JP2022524675A patent/JP2023501146A/ja active Pending
- 2020-11-04 WO PCT/EP2020/080941 patent/WO2021089609A1/en not_active Ceased
- 2020-11-04 EP EP20799711.5A patent/EP4055045A1/en active Pending
- 2020-11-04 CA CA3159904A patent/CA3159904A1/en active Pending
- 2020-11-04 AU AU2020379182A patent/AU2020379182A1/en active Pending
- 2020-11-04 CN CN202080091252.3A patent/CN114981306A/zh active Pending
- 2020-11-04 KR KR1020227018543A patent/KR20220092949A/ko active Pending
-
2022
- 2022-05-03 IL IL292727A patent/IL292727A/en unknown
-
2025
- 2025-01-29 JP JP2025012821A patent/JP2025078629A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025078629A5 (https=) | ||
| CN108610420B (zh) | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 | |
| Hayden et al. | Antibody engineering | |
| IL295604A (en) | Methods of making chimeric antigen receptor-expressing cells | |
| KR20230024984A (ko) | Cd70-지시 암 면역요법용 유전적으로 변형된 자연 살해 세포 | |
| JP2022548796A5 (https=) | ||
| JP2022514693A5 (https=) | ||
| IL312224B1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| HRP20251135T1 (hr) | Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| CN106883297A (zh) | 基于ch3结构域的异二聚体分子、其制备方法及用途 | |
| CN114127111A (zh) | 与nkp30结合的抗体分子及其用途 | |
| US20220396635A1 (en) | Trivalent binding molecules | |
| JP2025508316A5 (https=) | ||
| RU2017129591A (ru) | МАт-НАПРАВЛЯЕМЫЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРНЫЕ СИСТЕМЫ ДЛЯ СОРТИРОВКИ/ИСТОЩЕНИЯ СКОНСТРУИРОВАННЫХ ИММУННЫХ КЛЕТОК | |
| JP2024508672A5 (https=) | ||
| CN104829727B (zh) | 一种双特异性抗体cd19×cd3的构建及应用 | |
| JP2023525720A5 (https=) | ||
| JP2020535796A5 (https=) | ||
| JP2024511423A5 (https=) | ||
| EP4204096A2 (en) | Antibody molecules that bind to nkp30 and uses thereof | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| US20230002488A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| CA3180507A1 (en) | Heterodimeric proteins | |
| Loh et al. | Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies |